ArticleAging clinical and experimental research2026
Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology.
Article in Aging clinical and experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fracture Risk Stratification by REMS: A 5 Years Prospective Longitudinal Multicentre Study.Calcified tissue international · 2026Observational
- Methodological Clarification and Analysis of Demographic and Anthropometric Determinants in the Calculation of REMS Bone Mineral Density.Calcified tissue international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRomosozumab/AMG785 (Evenity
aimsTo assess the effectiveness of the radiation-free Radiofrequency Echographic Multi Spectrometry (REMS) for very short-term monitoring of RMZ in postmenopausal women.
methodsSeventy-four postmenopausal women starting RMZ and 52 postmenopausal women not receiving anti-osteoporosis drugs underwent proximal femur REMS scans at baseline and after 6 months, assessing total hip (TH) and femoral neck (FN) BMD. Exploratory analyses were also performed in treatment-naïve patients and in women with ≥ 2 prior fragility fractures.
resultsAfter six months of RMZ, BMD significantly increased at both TH (+ 3.7%; 0.718 ± 0.103 g/cm
conclusionsREMS detected clinically-relevant 6-month increases in femoral BMD during RMZ therapy, while BMD remained stable in untreated controls. These findings, together with anthropometric stability, support the feasibility of REMS for very short-term follow-up in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.